- Home
- IMMR vs PVLA Comparison
IMMR vs PVLA Comparison
Compare IMMR & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMMR | PVLA |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.4M | 1.1B |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | IMMR | PVLA |
|---|---|---|
| Price | $6.92 | $97.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 16 |
| Target Price | $12.25 | ★ $124.25 |
| AVG Volume (30 Days) | ★ 582.3K | 259.5K |
| Earning Date | 12-19-2025 | 11-11-2025 |
| Dividend Yield | ★ 4.33% | N/A |
| EPS Growth | ★ 57.07 | N/A |
| EPS | ★ 2.04 | N/A |
| Revenue | ★ $163,133,000.00 | N/A |
| Revenue This Year | $988.71 | N/A |
| Revenue Next Year | $109.72 | N/A |
| P/E Ratio | $3.45 | ★ N/A |
| Revenue Growth | ★ 338.21 | N/A |
| 52 Week Low | $5.65 | $11.17 |
| 52 Week High | $10.72 | $106.71 |
Technical Indicators
Market Signals| Indicator | IMMR | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 59.02 |
| Support Level | $6.83 | $95.28 |
| Resistance Level | $7.14 | $100.00 |
| Average True Range (ATR) | 0.27 | 6.07 |
| MACD | 0.05 | -0.60 |
| Stochastic Oscillator | 73.19 | 42.95 |
Price Performance
Historical ComparisonAbout IMMR Immersion Corporation
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.